Top

Published in:

01-02-2013 | Editorial

TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider?

Authors: Myriem Boufraqech, Catsim Fassassi, Electron Kebebew

Published in: Endocrine | Issue 1/2013

Excerpt

Activated toll-like receptor (TLR) signaling pathway has been reported in several endocrine neoplasms and has been found to be associated with the upregulation of proinflammatory cytokines. These cytokines are widely known as critical mediators of tumorigenesis. The stimulation of antitumor immunity through the activation of the TLR pathway can lead to the inhibition of the carcinogenesis process. However, TLRs have been considered as putative therapeutic target in various human cancers. A chronic inflammation in the absence of infection induces oxidative stress, DNA damage, and tissue damage promoting tumorigenesis. Thus, TLRs can be viewed as having a double-edged sword function. …

P. Pimentel-Nunes, L. Afonso, P. Lopes, R. Roncon-Albuquerque Jr, N. Goncalves, R. Henrique, L. Moreira-Dias, A.F. Leite-Moreira, M. Dinis-Ribeiro, Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol. Oncol. Res. POR 17(3), 677–683 (2011). doi:10.1007/s12253-011-9368-9 CrossRef

S. Gonzalez-Reyes, L. Marin, L. Gonzalez, L.O. Gonzalez, J.M. del Casar, M.L. Lamelas, J.M. Gonzalez-Quintana, F.J. Vizoso, Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10, 665 (2010). doi:10.1186/1471-2407-10-665 PubMedCrossRef

S. Gonzalez-Reyes, J.M. Fernandez, L.O. Gonzalez, A. Aguirre, A. Suarez, J.M. Gonzalez, S. Escaff, F.J. Vizoso, Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol. Immunother. CII 60(2), 217–226 (2011). doi:10.1007/s00262-010-0931-0 CrossRef

Q. Jiang, H. Wei, Z. Tian, Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 8, 12 (2008). doi:10.1186/1471-2407-8-12 PubMedCrossRef

K.D. McCall, N. Harii, C.J. Lewis, R. Malgor, W.B. Kim, M. Saji, A.D. Kohn, R.T. Moon, L.D. Kohn, High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 148(9), 4226–4237 (2007). doi:10.1210/en.2007-0459 PubMedCrossRef

J. Hagstrom, A. Heikkila, P. Siironen, J. Louhimo, I. Heiskanen, H. Maenpaa, J. Arola, C. Haglund, TLR-4 expression and decrease in chronic inflammation: indicators of aggressive follicular thyroid carcinoma. J. Clin. Pathol. 65(4), 333–338 (2012). doi:10.1136/jclinpath-2011-200402 PubMedCrossRef

K.S Kim, K. Hong II, Y.G. Eun, J. Chung, A missense polymorphism (rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population. Endocrine (2012). doi:10.1007/s12020-012-9783-z

V.L. Stevens, A.W. Hsing, J.T. Talbot, S.L. Zheng, J. Sun, J. Chen, M.J. Thun, J. Xu, E.E. Calle, C. Rodriguez, Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int. J. Cancer J. Int. du Cancer 123(11), 2644–2650 (2008). doi:10.1002/ijc.23826

J.P. Russell, S. Shinohara, R.M. Melillo, M.D. Castellone, M. Santoro, J.L. Rothstein, Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 22(29), 4569–4577 (2003). doi:10.1038/sj.onc.1206759 PubMedCrossRef

10.

J.P. Russell, J.B. Engiles, J.L. Rothstein, Proinflammatory mediators and genetic background in oncogene mediated tumor progression. J. Immunol. 172(7), 4059–4067 (2004)PubMed

11.

B. Belletti, P. Ferraro, C. Arra, G. Baldassarre, P. Bruni, S. Staibano, G. De Rosa, G. Salvatore, A. Fusco, M.G. Persico, G. Viglietto, Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 18(34), 4860–4869 (1999). doi:10.1038/sj.onc.1202869 PubMedCrossRef

12.

H. Sumimoto, F. Imabayashi, T. Iwata, Y. Kawakami, The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203(7), 1651–1656 (2006). doi:10.1084/jem.20051848 PubMedCrossRef

13.

I. Okayasu, The relationship of lymphocytic thyroiditis to the development of thyroid carcinoma. Endocr. Pathol. 8(3), 225–230 (1997)PubMedCrossRef

14.

M.E. Tabangin, J.G. Woo, L.J. Martin, The effect of minor allele frequency on the likelihood of obtaining false positives. BMC Proc. 3(Suppl 7), S41 (2009). doi:10.1186/1753-6561-3-S7-S41 PubMedCrossRef

Title: TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider?
Authors: Myriem Boufraqech
Catsim Fassassi
Electron Kebebew
Publication date: 01-02-2013
Publisher: Springer US
Published in: Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9827-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2013

Role of mineralocorticoid receptors on the hypothalamus–pituitary–adrenal axis in humans

1,5-Anhydroglucitol in diabetes mellitus

A missense polymorphism (rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population

Association study of a common variant near IRS1 with type 2 diabetes mellitus in Chinese Han population

Recurrent lymphoma in the thyroid gland detected by fluorine-18-fluorodeoxyglucose PET/CT

Proton pump inhibitors: impact on glucose metabolism

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page